Cartesian Therapeutics Azioni (NASDAQ: RNAC)

Ultime notizie per Cartesian Therapeutics (NASDAQ:RNAC) Azioni

Cartesian Therapeutics

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics Inc

RBC Capital analyst James McGarragle reiterates Exchange Income (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EIF#TSX">EIF</a>) with a Outperform and maintains C$71 price target.

News

Price Target

Reiteration

Analyst Ratings

TSX:EIF

RBC Capital Reiterates Outperform on Exchange Income, Maintains C$71 Price Target

JP Morgan analyst David Karnovsky maintains Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) with a Overweight and lowers the price target from $41 to $40.

JP Morgan Maintains Overweight on Warner Music Gr, Lowers Price Target to $40

WIIM

GRAB

Grab Holdings shares are trading lower after B of A Securities downgraded the stock from Buy to Underperform, maintaining its price target at $4.90.

JP Morgan analyst Daniel Chen maintains iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) with a Neutral and lowers the price target from $2.5 to $1.8.

JP Morgan Maintains Neutral on iQIYI, Lowers Price Target to $1.8

RBC Capital analyst Darko Mihelic reiterates Manulife Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MFC#TSX">MFC</a>) with a Outperform and maintains C$49 price target.

TSX:MFC

RBC Capital Reiterates Outperform on Manulife Financial, Maintains C$49 Price Target

A poll of Benzinga readers found that they don't believe Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) should be broken up. This comes as the Department of Justice (DOJ) suggested divesting the Chrome browser to <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">break a search monopoly.</a>
What Happened: Google parent Alphabet has long <a href="https://www.benzinga.com/government/21/07/22094354/could-new-justice-department-hire-lead-to-google-breakup">been a target</a> of potential antitrust investigations due to the company's large market share in online search.
The DOJ recommended that Google share search data with competitors to foster fair competition. The department also said Google should consider selling its Android operating system.
"Google's unlawful behavior has deprived rivals not only of critical distribution channels but also distribution partners who could otherwise enable entry into these markets by competitors in new and innovative ways," the DOJ&nbsp;said in a statement.
A recent poll of Benzinga readers found that they don't believe Alphabet should be split up.
"Should the Department of Justice break up Alphabet (Google)?" Benzinga asked.
The results were:
<ul>
<li>Yes: 36%</li>
<li>No: 64%</li>
</ul>
While the DOJ is targeting Chrome as the potential unit to be divested, Benzinga readers have other preferences.
"Which part of Alphabet would you most want to invest in if it splits up," Benzinga asked.
The results were:
<ul>
<li>YouTube: 43%</li>
<li>Google Search: 31%</li>
<li>Android: 17%</li>
<li>Chrome: 9%</li>
</ul>
Benzinga readers ranked YouTube as the top choice for a standalone unit, while Chrome was the least favored.
Read Also: <a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale">Alphabet Bleeds Over $120 Billion In Market Value, Eyes Worst Day In 10 Months After DOJ Demands Google Chrome Sale</a>
Why It's Important: While Alphabet likely does not want to split up or sell any of its units, investors could end up the winners <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40378964/google-stock-swings-on-doj-investigation-analyst-says-googl-is-worth-more-in-pieces">according to analysts.</a>
Jefferies analyst Brent Thill recently said that a breakup or business separation could be good for shareholders.
&#8220;We don&#8217;t believe a full breakup would happen. Even if it did, it would be good for shareholders because the sum of the parts is greater than the whole,&#8221; Thill&nbsp;<a href="https://x.com/YahooFinance/status/1823722376716280107" target="_blank" rel="noreferrer noopener">told&nbsp;</a>Yahoo Finance.
Needham analyst Laura Martin has been emphasizing for months that a forced breakup of Alphabet could lead to a significantly higher valuation.
&#8220;We believe that GOOGL is worth more in pieces than together, so we welcome regulators&#8217; attempts to break up GOOGL,&#8221; Martin said in a new investor note.
A break-up could put a spotlight on the valuation of video platform YouTube, Martin said.
&#8220;We calculate that YouTube would be valued between $455B-$643B if separately traded.&#8221;
Martin said Alphabet shares would likely trade higher if the company breaks up because investors would be willing to pay more for &#8220;pure-play assets,&#8221; more data points could be publicly shared, and employees would receive shares in business lines they directly impact.
Martin has a Buy rating on Alphabet and price target of $210.
GOOG Price Action: Alphabet stock trades at $167.81 Friday versus a 52-week trading range of $129.40 to $193.31. Alphabet stock is up 21.3% year-to-date, trailing the 25.6% gain of the SPDR S&amp;P 500 ETF Trust, which tracks the S&amp;P 500.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42131274/why-googles-chrome-battle-isnt-just-about-search-gene-munster-calls-it-a-tough-day-for-big-tech-on-the-regulatory-front">Google&#8217;s Chrome Battle Goes Beyond The Browser: Gene Munster Outlines Wider Implications Of DOJ Going After The Search Giant</a></li>
</ul>
The study was conducted by Benzinga from Nov. 21 through Nov. 22, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 88 adults.
Photo: Shutterstock

Exclusives

Tech

Trading Ideas

GOOG

GOOGL

DOJ Targets Google Chrome, Poll Shows 64% Oppose Alphabet Breakup: YouTube Seen As Top Prize

SMCI

Super Micro Computer shares are trading higher. The company on Wednesday announced it submitted a compliance plan to Nasdaq.

U.S. stocks traded higher this morning, with the Dow Jones index gaining by more than 300 points on Friday.
Following the market opening Friday, the Dow traded up 0.72% to 44,184.62 while the NASDAQ rose 0.07% to 18,985.33. The S&amp;P 500 also rose, gaining, 0.35% to 5,969.29.
Check This Out: <a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a>
Leading and Lagging Sectors Consumer staples shares rose by 1% on Friday.
In trading on Friday, communication services shares fell by 0.4%.
Top Headline
Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) reported better-than-expected earnings for its second quarter and raised its outlook for FY24 gross margin.
&nbsp;The company reported quarterly earnings of 54 cents per share, which beat the analyst consensus estimate of 40 cents per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SKK Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) shares shot up 76% to $1.95 after declining around 75% on Wednesday.</li>
<li>Shares of DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) got a boost, surging 77% to $0.8931.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares were also up, gaining 48% to $16.37 after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares dropped 52% to $6.53 after the company announced the pricing of a $9 million underwritten public offering.</li>
<li>Shares of Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) were down 44% to $0.1374 after the company announced the pricing of an $8 million public offering.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) was down, falling 42% to $0.1148 after the company announced its board approved a 1-for-35 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $70.67 while gold traded up 0.9% at $2,697.70.
Silver traded up 1.2% to $31.33 on Thursday, while copper fell 0.8% to $4.0910.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.2%, Germany's DAX gained 0.9% and France's CAC 40 rose 0.7%. Spain's IBEX 35 Index rose 0.2%, while London's FTSE 100 gained 1.4%.
The S&amp;P Global UK composite PMI declined to 49.9 in November versus 51.8 in the previous month, while Eurozone composite PMI dipped to 48.1 in November from 50 in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.68%, Hong Kong's Hang Seng Index falling 1.89%, China's Shanghai Composite Index dipping 3.06% and India's BSE Sensex gaining 2.54%.
Economics
<ul>
<li>The S&amp;P Global US Services PMI climbed to 57 in November versus 55 in the previous month, while manufacturing PMI increased to 48.8 in November from 48.5 in the previous month.</li>
<li>The University of Michigan consumer sentiment for the US fell to 71.8 in November versus a preliminary reading of 73.</li>
<li>The year-ahead inflation expectations in the U.S fell to 2.6% in November from 2.7% in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42135946/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

Eurozone

Intraday Update

Markets

AMIX

APTO

CETX

DEVS

REPL

Dow Jumps 300 Points; Gap Posts Upbeat Earnings

RBC Capital analyst Arthur Nagorny reiterates Mattr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MATR#TSX">MATR</a>) with a Outperform and maintains C$18 price target.

TSX:MATR

RBC Capital Reiterates Outperform on Mattr, Maintains C$18 Price Target

Stock Split

J-Long Group Announces 1-For-10 Reverse Stock Split

JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Overweight and lowers the price target from $45 to $15.

JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $15

Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) shares are trading higher on Friday. The company has agreed to sell its Personal Protective Equipment (PPE) business to Protective Industrial Products, Inc. (PIP) for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42135452/honeywell-to-sell-personal-protective-equipment-business-to-protective-industrial-products" rel="noreferrer noopener">$1.325 billion in an all-cash deal</a>.
This move aligns with Honeywell&#8217;s strategy to streamline its portfolio, focusing on core businesses and pursuing high-return acquisitions that support its three key megatrends: automation, the future of aviation, and energy transition.
This sale follows Honeywell&#8217;s 2021 divestiture of its Lifestyle and Performance Footwear Business to Rocky Brands for $230 million, marking the company&#8217;s exit from the PPE sector.
However, Honeywell will retain its gas detection portfolio within the Industrial Automation segment.
The sale of the PPE business is expected to close in the first half of 2025, pending customary conditions.
Vimal Kapur, Chairman and CEO of Honeywell said, &#8221;Now with this transaction, the business will be positioned to accelerate its growth trajectory as it benefits from Odyssey&#8217;s historic investing in the PPE sector and scaling similar businesses&nbsp;to expand into new products, geographies and end markets.&#8221;
&#8220;As we continue to simplify and optimize Honeywell&#8217;s portfolio, the sale of the PPE business will enable us to further strengthen our core business in alignment with our three compelling megatrends.&#8221;
&#8221;The combination of today&#8217;s announcement, with the strategic acquisitions we have made over the past year, positions us to continue to drive profitable growth and strong cash generation while creating compelling long-term value for our shareowners.&#8221;
Last month, Honeywell announced a plan to spin off its Advanced Materials business into an independent, U.S. publicly traded company, which is targeted to be <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41223435/honeywell-announces-plan-to-spin-off-advanced-materials-business-to-shareowners" rel="noreferrer noopener">completed by the end of 2025 or early 2026.</a>
Honeywell held cash and equivalents of about&nbsp;$10.6 billion as of <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41516652/honeywells-mixed-q3-eps-beats-misses-on-sales-and-lowers-fy24-revenue-outlook" rel="noreferrer noopener">September 30, 2024</a>.
Investors can gain exposure to the stock via&nbsp;Amplify CWP Enhanced Dividend Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIVO#NYSE">DIVO</a>) and&nbsp;Invesco Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPA#NYSE">PPA</a>).
Price Action: HON shares are up 1.01% at $228.38 at the last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42137748" target="_blank" rel="noreferrer noopener">Amid Ongoing Browser Antitrust Scrutiny In US, UK Might Be Next To Challenge Apple And Google&#8217;s Duopoly</a></li>
</ul>

Large Cap

Asset Sales

DIVO

Honeywell Cashes Out: $1.325 Billion PPE Business Sale Fuels Bold Portfolio Transformation

$BTC

CBOE

Cboe To Launch First Cash-Settled Spot Bitcoin Index Options On December 2, Expanding Investor Access To Crypto Derivatives

JP Morgan analyst Andrew Steinerman maintains Vestis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) with a Neutral and raises the price target from $15 to $16.

VSTS

JP Morgan Maintains Neutral on Vestis, Raises Price Target to $16

Elon Musk and <a href="https://www.benzinga.com/startups/24/11/42038767/im-one-of-you-how-anti-woke-warrior-vivek-ramaswamy-became-a-billionaire-at-only-38">Vivek Ramaswamy</a> have been appointed to lead a new <a href="https://www.benzinga.com/news/24/11/42026862/musk-and-ramaswamy-seek-spending-cut-wins-where-others-failed">government-efficiency commission</a> created by Donald Trump. The stated goal is to cut government spending and one approach being considered involves reducing or eliminating certain federal agencies.&nbsp;
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
As Business Insider reports, while Ramaswamy expects to &#8220;delete&#8221; whole government agencies, Musk emphasized that the plan is not to leave people without support but to streamline the federal workforce in areas they consider &#8220;bloated.&#8221; He has mentioned the possibility of offering severance packages of up to two years&#8217; pay to those affected.
According to official government data, 2,278,730 Americans worked for the federal government as of March 2024. Some departments are significantly larger than others. For example, the <a href="https://www.benzinga.com/24/11/42021130/with-doug-collins-as-va-leader-whats-next-for-cannabis-and-psychedelics-in-veterans-healthcare">Department of Veterans Affairs</a> employs nearly half a million people, while the Department of Education has just over 4,000 employees. Within the Treasury Department, most of the 100,000+ employees work for the Internal Revenue Service (IRS).
Departments with more than 100,000 employees:
<ul>
<li>Department of Veterans Affairs (486,522)</li>
<li>Department of Homeland Security (222,539)</li>
<li>Department of the Army (221,037)</li>
<li>Department of the Navy (216,537) </li>
<li>Department of the Air Force (168,505)</li>
<li>Department of Defense (156,803)</li>
<li>Department of Justice (116,614)</li>
<li>Department of the Treasury (108,869)</li>
</ul>
See Also: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
Many federal workers earn competitive salaries, with most departments offering six-figure averages. The Department of Education <a href="https://www.benzinga.com/markets/equities/24/09/40963177/us-department-of-energy-to-invest-3b-in-battery-production">and Energy</a> tend to have the highest average salaries among government agencies, at $144,561 and $143,486, respectively.
Departments with the highest average salary:
<ul>
<li>Department of Education ($144,561)</li>
<li>Department of Energy ($143,486)</li>
<li>Department of Transportation ($139,474)</li>
<li>Department of Housing and Urban Development ($134,503)</li>
<li>Department of State ($132,587)</li>
<li>Department of Health and Human Services ($130,117)</li>
</ul>
This is not the first time a commission like this has been formed. According to Business Insider, Ronald Reagan had the Grace Commission in the 1980s, which aimed to find waste and inefficiencies in federal spending. However, it is important to note that Musk and Ramaswamy&#8217;s new effort does not have the authority to make these changes on its own – it will need Congress to back its recommendations.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We are very grateful to the thousands of Americans who have expressed interest in helping us at DOGE. We don't need more part-time idea generators. We need super high-IQ small-government revolutionaries willing to work 80+ hours per week on unglamorous cost-cutting. If that's…
&mdash; Department of Government Efficiency (@DOGE) <a href="https://twitter.com/DOGE/status/1857076831104434289?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
To fulfill their goals, <a href="https://www.benzinga.com/news/24/11/41998717/elon-musk-and-vivek-ramaswamy-are-looking-for-high-iq-small-government-revolutionaries-who-are-willing-to-put-in-80-hours-at-doge">Musk and Ramaswamy are seeking</a> &#8220;super high-iQ small-government revolutionaries&#8221; to help reduce federal inefficiencies under President-elect Donald Trump. DOGE&#8217;s official account on X posted a call for applicants willing to work 80+ hours a week to streamline government spending and cut bureaucracy. Interested candidates are encouraged to DM their CVs, with Musk and Ramaswamy supposedly personally reviewing the top 1% of applicants.
While Musk and Ramaswamy&#8217;s approach aims to make the government &#8220;leaner&#8221; and potentially more efficient, there are significant concerns regarding the impact of such drastic cuts. Eliminating entire agencies could result in disruptions to essential public services, affecting everything from health care to education to veterans&#8217; support. The loss of federal jobs could also have a broader economic impact, particularly in regions where government employment forms a significant part of the local economy.&nbsp;
Read Next:
<ul>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a></li>
</ul>

With Musk And Ramaswamy Preparing To Slash Entire Government Agencies, Here's Which Departments Employ The Most Americans And Their Salaries

In the current session, the stock is trading at $145.85, after a 0.73% spike. Over the past month, Cava Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) stock increased by 7.08%, and in the past year, by 333.82%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732288513_0.png" alt="Past Year Chart" />

<h3>Cava Group P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Cava Group has a better P/E ratio of 353.17 than the aggregate P/E ratio of 69.6 of the Hotels, Restaurants &amp; Leisure industry. Ideally, one might believe that Cava Group Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732288513_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

CAVA

Price Over Earnings Overview: Cava Group

JP Morgan analyst Matthew Boss maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Neutral and raises the price target from $26 to $28.

JP Morgan Maintains Neutral on Gap, Raises Price Target to $28

JP Morgan analyst Matthew Boss maintains Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) with a Overweight and raises the price target from $171 to $173.

ROST

JP Morgan Maintains Overweight on Ross Stores, Raises Price Target to $173

Keybanc analyst Jason Celino maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Overweight and raises the price target from $68 to $85.

PCOR

Keybanc Maintains Overweight on Procore Technologies, Raises Price Target to $85

Stifel analyst Simon Yarmak upgrades Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) from Hold to Buy and raises the price target from $14.75 to $15.

Upgrades

Stifel Upgrades Pebblebrook Hotel to Buy, Raises Price Target to $15

Analyst Gil Blum from Needham maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) and keeping the price target at $41.00. Gi...

Promising Phase IIb Results and Sustained Efficacy Bolster Buy Rating for Cartesian Therapeutics

Mizuho Securities analyst Uy Ear has maintained their bullish stance on RNAC stock, giving a Buy rating today. Uy Ear has given his Buy rating due ...

Buy Rating for Cartesian Therapeutics Supported by Promising Descartes-08 Phase 2b Results and Upcoming Catalysts

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) today. The company's shares closed last...

TD Cowen Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) today. The company's shares opened toda...

TD Cowen Remains a Buy on Cartesian Therapeutics (RNAC)

Needham analyst Gil Blum has maintained their bullish stance on RNAC stock, giving a Buy rating today. Gil Blum has given his Buy rating due to a c...

Positive Outlook for Cartesian Therapeutics: Buy Rating Driven by Promising Study Results and Strategic Initiatives

In a report released today, Matthew Biegler from Oppenheimer maintained a Hold rating on Cartesian Therapeutics (RNAC – Research Report). The compa...

Cartesian Therapeutics (RNAC) Receives a Hold from Oppenheimer

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cartesian Therapeutics (RNAC – Research Report), Allogene Therape...

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Allogene Therapeutics (ALLO) and Moderna (MRNA)

Cartesian Therapeutics, Inc. ( ($RNAC) ) has released its Q3 earnings. Here is a breakdown of the information Cartesian Therapeutics, Inc. presente...

Cartesian Therapeutics Reports Q3 2024 Financial Results

Cartesian Therapeutics: Uncertainty Remains

Thomas Smith, an analyst from Leerink Partners, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

Cartesian Therapeutics Receives Buy Rating After Promising Phase 2b Trial Results and Strategic Advancements

ALLO

ARGX

MRNA

RNAC

Health Care

Press Releases

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting

Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Comments

Cartesian Therapeutics

Notizie

Ultime notizie per Cartesian Therapeutics (NASDAQ:RNAC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO